Abstract
Sertraline is a safe and effective agent frequently used in the treatment of childhood depression and obsessive compulsive disorder. Amotivational syndrome is also an important clinical manifestation characterized by decreased capacity to make and carry out long-term plans and lack of motivation. This report describes the development of amotivational syndrome in a 12-year-old girl receiving sertraline monotherapy and successful management of this side effect with discontinuation of sertraline and initiation of fluoxetine therapy. This case is presented because, to the best of our knowledge, there have been very few case reports regarding the development of sertraline-related amotivational syndrome and, more importantly, because of the very low number of case reports in which amotivational syndrome was managed by switching to a different selective serotonin reuptake inhibitor.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
